Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 19~* Patients who understood the contents and purpose of this trial and signed informed consent form~* Patients with essential hypertension and dyslipidemia~Exclusion Criteria:~* Patients with differences between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP~* Patients with mean sitSBP ≥ 180 mmHg or mean sitDBP ≥ 110 mmHg~* Concomitant administration of cyclosporine~* Tolerance or Hypersensitivity Angiotensin II receptor blocker or HMG-CoA reductase inhibitor, Calcium channel blocker(dihydropyridine) or Multi-drug allergy~* Hereditary angioedema or medical history of angioedema in the treatment of ACE inhibitors or angiotensin II receptor blockers~* Fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse effect to statin~* CPK normal range \> 2 times~* Secondary hypertension and suspected secondary hypertension~* Orthostatic hypotension with symptoms~* Uncontrolled primary hypothyroidism(TSH normal range ≥ 1.5 times)~* Severe hepatopathy or active hepatopathy (AST or ALT normal range ≥ 3 times)~* Active gout or hyperuricemia(uric acid ≥ 9mg/dL)~* IDDM or uncontrolled type 2 diabetes mellitus (HbA1c \> 9%)~* Ventricular arrhythmia~* Medical history~  * Severe heart disease(heart failure of NYHA class III-IV)~ * Severe cerebrovascular disease within 6 months (cerebral infarction, cerebral hemorrhage), hypertensive encephalopathy, transient cerebral ischemic attack(TIA)~ * Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant stenosis in aortic valve or mitral valve~ * Ischemic heart disease(myocardial infarction, angina) within 6months~ * Angioplasty or coronary artery bypass graft(CABG) surgery within 6months

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): HCP1701
- Active Comparator 1 (Type: ACTIVE_COMPARATOR): HGP0904, HGP0608
- Active Comparator 2 (Type: ACTIVE_COMPARATOR): HGP0608, HCP1306

Based on this trial design, predict the completion outcome and termination type (if applicable).